Omeros Corporation (Nasdaq: OMER) announced its financial results for the fourth quarter and year ended December 31, 2025, showcasing a significant turnaround with a net income of $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the same period in 2024. The company attributed this positive outcome to a net gain of $237.6 million from the sale of its lead monoclonal antibody, zaltenibart, to Novo Nordisk Health Care AG. This transaction not only provided substantial upfront cash but also positions Omeros for future milestone payments totaling up to $1.3 billion, contingent on the success of zaltenibart in clinical development.

In addition to the impressive financial results, Omeros reported a decrease in total operating expenses for the year, which amounted to $122.8 million, down from $167.0 million in 2024. This reduction was primarily due to strategic cost management and the timing of manufacturing batches. The company also highlighted a significant decrease in its debt, with total liabilities dropping from $164.9 million in 2024 to $87.9 million by the end of 2025.

Omeros' recent achievements include the FDA approval of YARTEMLEA (narsoplimab-wuug) for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), marking it as the first approved therapy for this condition. The commercial launch of YARTEMLEA began in January 2026, with both adult and pediatric patients now receiving treatment.

Looking ahead, Omeros is optimistic about its strategy and operational execution, aiming for positive cash flow by 2027. The company plans to leverage its partnership with Novo Nordisk to expand the indications for zaltenibart while continuing to develop its robust pipeline of therapeutics targeting complement-mediated diseases and oncology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.